



ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

November 1, 2006

SAN DIEGO--(BUSINESS WIRE)--Nov. 1, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:

- The Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8, 2006 at 11:20 a.m. Eastern Time at The New York Palace Hotel in New York City.
- The San Diego BIOCOM Investor Conference on Wednesday, November 15, 2006 at 9:20 a.m. Pacific Time at the San Diego Marriott Del Mar in San Diego.
- The JMP Securities Sector Focus Conference on Thursday, November 16, 2006 at 10:00 a.m. Eastern Time at the Four Seasons Hotel in Boston.
- The Piper Jaffray Healthcare Conference on Wednesday, November 29, 2006 at 10:00 a.m. Eastern Time at the Pierre Hotel in New York City.

Live webcasts of these presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for two weeks following the presentation.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five Phase II-stage clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmö, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and
Chief Financial Officer
858-558-2871